The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1478
Flibanserin (Addyi) for Hypoactive Sexual Desire Disorder
The full article is available to subscribers Subscriber Login   
Revised 10/20/15: The price for flibanserin has been included in the Cost paragraph.

The FDA has approved flibanserin (Addyi – Sprout) for treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) not caused by another medical or psychiatric condition, the effects of another drug, or relationship difficulties. Flibanserin is the first drug to be approved for treatment of HSDD. It is not approved for use in men or postmenopausal women. Previous FDA reviews of flibanserin in 2010 and 2013 did not result in approval.

THE DISORDER — HSDD is defined as a deficiency or lack of sexual thoughts or desire that causes personal distress or interpersonal difficulty. It is characterized as lifelong or acquired, and as situational (related to a specific partner, situation, or type of stimulation) or generalized. Estimates of the prevalence of HSDD in women vary widely; one study found that 14% of premenopausal women 20-49 years old have HSDD. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Flibanserin (Addyi) for Hypoactive Sexual Desire Disorder
Article code: 1478a
 Electronic, downloadable article - $25